Greg Harrison
Stock Analyst at Scotiabank
(2.05)
# 2,817
Out of 4,712 analysts
61
Total ratings
38.78%
Success rate
-5.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $426 → $430 | $409.63 | +4.97% | 3 | Dec 23, 2024 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $77 → $44 | $16.85 | +161.21% | 4 | Dec 13, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $53 → $75 | $34.53 | +117.23% | 4 | Dec 9, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $45 → $48 | $28.23 | +70.03% | 3 | Nov 25, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $35 → $30 | $33.22 | -9.69% | 2 | Nov 6, 2024 | |
| IRON Disc Medicine | Maintains: Sector Outperform | $62 → $70 | $65.23 | +7.31% | 2 | Nov 5, 2024 | |
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $23 → $27 | $17.14 | +57.53% | 7 | Nov 1, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $305 → $310 | $242.29 | +27.95% | 2 | Nov 1, 2024 | |
| VERA Vera Therapeutics | Initiates: Sector Outperform | $60 | $42.03 | +42.77% | 1 | Oct 16, 2024 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Sector Outperform | $18 | $7.26 | +147.93% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $24 | $28.90 | -16.96% | 3 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $11.60 | +158.62% | 4 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $6 | $3.33 | +80.45% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $11.70 | +327.35% | 3 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $8.41 | +161.59% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $1.24 | +1,114.57% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $303 → $280 | $364.09 | -23.10% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $12.11 | +651.45% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.38 | +5.45% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $2.43 | -38.27% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $12.64 | +208.54% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $10.36 | -71.04% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $4.12 | +1,599.03% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $15.59 | -48.69% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $22.52 | +139.79% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 → $6 | $0.90 | +569.12% | 5 | Mar 14, 2022 |
Vertex Pharmaceuticals
Dec 23, 2024
Maintains: Sector Perform
Price Target: $426 → $430
Current: $409.63
Upside: +4.97%
Keros Therapeutics
Dec 13, 2024
Maintains: Sector Outperform
Price Target: $77 → $44
Current: $16.85
Upside: +161.21%
Agios Pharmaceuticals
Dec 9, 2024
Maintains: Sector Outperform
Price Target: $53 → $75
Current: $34.53
Upside: +117.23%
BridgeBio Pharma
Nov 25, 2024
Maintains: Sector Outperform
Price Target: $45 → $48
Current: $28.23
Upside: +70.03%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Sector Perform
Price Target: $35 → $30
Current: $33.22
Upside: -9.69%
Disc Medicine
Nov 5, 2024
Maintains: Sector Outperform
Price Target: $62 → $70
Current: $65.23
Upside: +7.31%
Travere Therapeutics
Nov 1, 2024
Maintains: Sector Outperform
Price Target: $23 → $27
Current: $17.14
Upside: +57.53%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Sector Outperform
Price Target: $305 → $310
Current: $242.29
Upside: +27.95%
Vera Therapeutics
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $60
Current: $42.03
Upside: +42.77%
EyePoint Pharmaceuticals
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $7.26
Upside: +147.93%
Oct 16, 2024
Initiates: Sector Perform
Price Target: $24
Current: $28.90
Upside: -16.96%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $30
Current: $11.60
Upside: +158.62%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $6
Current: $3.33
Upside: +80.45%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $50
Current: $11.70
Upside: +327.35%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $8.41
Upside: +161.59%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $1.24
Upside: +1,114.57%
Aug 1, 2024
Maintains: Underperform
Price Target: $303 → $280
Current: $364.09
Upside: -23.10%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $12.11
Upside: +651.45%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.38
Upside: +5.45%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $2.43
Upside: -38.27%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $12.64
Upside: +208.54%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $10.36
Upside: -71.04%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $4.12
Upside: +1,599.03%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $15.59
Upside: -48.69%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $22.52
Upside: +139.79%
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $0.90
Upside: +569.12%